S

Sanofi

Global pharma company; vaccines and R&D

Protein Machine Learning Senior Principal Data Scientist

Full-TimeUpdated Deadline 1/8/27
$148.5k - $214.5k
Expert
PhD
Waltham, MA, USA
In PersonOnsite in Waltham, Massachusetts.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A PhD degree in Computational Biology, Data Science, Applied Mathematics, Biophysics, or a closely related field is required.
  • At least 2 years of experience in an industry or academic setting.
  • Advanced proficiency in Python, R, and SQL, with hands-on experience in PyTorch and AI-based structural modeling tools such as AlphaFold, OpenFold, and Boltz.
  • Demonstrated ability to communicate in writing and in person across computational and bench lab teams, adapting messaging to diverse audiences including senior leadership.
  • Strong problem-solving, communication, and collaboration skills across multidisciplinary teams.
  • Fluent English is required.
Responsibilities
  • Develop protein property prediction models focused on immunogenicity, stability, and manufacturability to support vaccine design.
  • Leverage and refine language-based foundational protein representations to accelerate identification and optimization of vaccine candidates.
  • Analyze relationships between protein sequences, structures, and functional data to uncover generalizable representations applicable across vaccine programs.
  • Collaborate with structural biology, protein design, and bench lab teams to shape protein modeling strategy and iteratively improve model quality.
  • Maintain the modeling codebase according to best coding practices, ensuring results are robust, reproducible, and well-documented.
  • Mentor and upskill colleagues on advances in protein modeling tools and techniques.
  • Communicate scientific findings to internal and external stakeholders, adapting the level of detail to each audience.
Desired Qualifications
  • A track record in computational biology, including protein language models, biophysics, and development of AI-based predictive models; prior experience with immunogenicity predictors is a plus.
  • Deep knowledge of protein representation models such as ESM.
  • Familiarity with molecular dynamics, next-generation sequencing analysis, and deep mutational scanning.
  • Familiarity with agentic tools such as Claude Code for automated software engineering is strongly preferred.
  • Ability to mentor junior colleagues and lead collaboratively in protein modeling.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...